SCHEMBL6317068

SCHEMBL6317068

CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc(-c2ccccc2)cc1)N(C)C(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
REN P00797 1/20 0.46
CTSS P25774 4/20 0.45
CTSK P43235 3/20 0.45
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
MMP13 P45452 1/20 0.42
MME P08473 2/20 0.41
ACE P12821 2/20 0.41
ACE2 Q9BYF1 2/20 0.41
CPA1 P15085 1/20 0.41
CTSB P07858 2/20 0.40
CTSL P07711 1/20 0.40
MMP3 P08254 2/20 0.40
MMP2 P08253 1/20 0.39
ITGA4 P13612 1/20 0.39
ITGB7 P26010 1/20 0.39
BCL2 P10415 1/20 0.39
AKT1 P31749 1/20 0.38
GHSR Q92847 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4426560 0.90 REN (0.50) RENCTSSCTSKMMP13ACE
SCHEMBL7368069 0.88 GHSR (0.49) RENCTSSCTSKMMP13CTSB
SCHEMBL4428281 0.88 GHSR (0.49) RENCTSSCTSKMMP13CTSB
SCHEMBL3267330 0.87 ALDH1A1 (0.44) RENCTSSCTSKALDH1A1MAPT
SCHEMBL6317975 0.85 PPARA (0.45) RENCTSSCTSKMMP13CTSB
SCHEMBL7063344 0.85 ALDH1A1 (0.49) ALDH1A1MAPTMMEACEACE2
SCHEMBL6317747 0.85 CTSS (0.46) RENCTSSCTSKMMP13MMP2
SCHEMBL3272874 0.85 REN (0.42) RENCTSSCTSKALDH1A1MAPT
SCHEMBL22457519 0.84 REN (0.55) RENCTSSCTSKMMP13MME
SCHEMBL6318037 0.83 CTSS (0.48) CTSSCTSKALDH1A1MAPTCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1184370-B1 Compounds with growth hormone releasing properties NOVO NORDISK AS (DK) 2005-09-14 EP disclosed
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
EP-1501830-A1 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES Actelion Pharmaceuticals Ltd. (CH) 2005-02-02 EP disclosed
WO-2003093267-A1 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES ACTELION PHARMACEUTICALS LTD (CH) 2003-11-13 WO disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
EP-1184370-A2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2002-03-06 EP disclosed
US-6274584-B1 PEPTIDE DERIVATIVES; BIOAVAILABILITY; ENZYME RESISTANCE; MILK AND WOOL PRODUCTION NOVO NORDISK A/S (DK) 2001-08-14 US disclosed
EP-0842178-B1 FUROPYRIDINE, THIENOPYRIDINE, PYRROLOPYRIDINE AND RELATED PYRIMIDINE, PYRIDAZINE AND TRIAZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION ABBOTT LAB (US) 2001-03-28 EP disclosed
EP-1005484-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 2000-06-07 EP disclosed
EP-0973777-A1 FUROPYRIDINE, THIENOPYRIDINE, PYRROLOPYRIDINE AND RELATED PYRIMIDINE, PYRIDAZINE AND TRIAZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION Abbott Laboratories (US) 2000-01-26 EP disclosed
US-6001849-A Furopyridine, thienopyridine pyrrolopyridine useful in controlling chemical synaptic transmission ABBOTT LABORATORIES (US) 1999-12-14 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
US-5922770-A NOVEL COMPOUNDS THAT STIMULATE THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 1999-07-13 US disclosed
WO-1998058950-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-12-30 WO disclosed
WO-1998046609-A1 FUROPYRIDINE, THIENOPYRIDINE, PYRROLOPYRIDINE AND RELATED PYRIMIDINE, PYRIDAZINE AND TRIAZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION ABBOTT LABORATORIES (US) 1998-10-22 WO disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed
US-5409946-A Antiepileptic agent ABBOTT LABORATORIES (US) 1995-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 REN 261/4885CTSS 2319/4885CTSK 1324/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR REN 263/4885CTSS 2636/4885CTSK 1778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.